Welcome

Modern mass spectrometry developments hold significant potential for the discovery and sensitive detection of innovative (sets of) biomarkers which will allow rapid and accurate diagnosis of multiple disorders simultaneously in a single patient’s small-volume sample.

ProteoFormiX is running a top-down proteomics-based translational biomarker discovery platform. We employ state-of-the-art and proprietary technology to identify disease-associated proteoforms (e.g., peptides) in clinically sampled human tissues and biofluids.

founder

ProteoFormiX was founded by Prof. Dr. Peter Verhaert in 2017. The company resides at JLABS@BE, the European Johnson & Johnson Innovation Center.

company profile

menu

About ProteoFormiX

Projects & Services

Team

Advisory Board

Partnerships / Industrial Support

Presence at International Scientific Meetings

News / Highlights

In the Media

Contact